Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 19/20 | 0.53 |
| ▸ | TACR2 | P21452 | 4/20 | 0.45 |
| ▸ | TAC3 | Q9UHF0 | 1/20 | 0.45 |
| ▸ | TACR3 | P29371 | 2/20 | 0.44 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.42 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30693211 | 1.00 | TACR1 (0.53) | TACR1TACR2TAC3TACR3SGMS1 | |
| SCHEMBL15397531 | 0.90 | TACR1 (0.50) | TACR1TACR2TAC3TACR3CYP3A4 | |
| SCHEMBL30693175 | 0.88 | TACR1 (0.53) | TACR1TACR2TAC3TACR3 | |
| SCHEMBL1973933 | 0.88 | TACR1 (0.53) | TACR1TACR2TAC3TACR3 | |
| SCHEMBL30693186 | 0.86 | TACR1 (0.46) | TACR1TACR2TAC3TACR3 | |
| SCHEMBL1972982 | 0.86 | TACR1 (0.46) | TACR1TACR2TAC3TACR3 | |
| SCHEMBL1972571 | 0.85 | TACR1 (0.57) | TACR1TACR2TAC3TACR3SGMS1 | |
| SCHEMBL30693185 | 0.85 | TACR1 (0.57) | TACR1TACR2TAC3TACR3SGMS1 | |
| SCHEMBL13801240 | 0.84 | TACR1 (0.49) | TACR1TACR2TAC3TACR3 | |
| SCHEMBL13801311 | 0.84 | TACR1 (0.49) | TACR1TACR2TAC3TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| EP-2336105-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | TACR1 13/4885TACR2 29/4885TAC3 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.